» Articles » PMID: 14992983

Treatment of Bulimia Nervosa in a Primary Care Setting

Overview
Journal Am J Psychiatry
Specialty Psychiatry
Date 2004 Mar 3
PMID 14992983
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The authors' goal was to determine whether treatments known to be effective for bulimia nervosa in specialized treatment centers can be used successfully in primary health care settings. They examined the benefits of two treatments for bulimia: 1) fluoxetine, an antidepressant medication, and 2) guided self-help, an adaptation of cognitive behavior therapy.

Method: Ninety-one female patients in two primary care settings were randomly assigned to receive fluoxetine alone, placebo alone, fluoxetine plus guided self-help, or placebo and guided self-help.

Results: The majority of the patients did not complete the treatment trial; many patients found the treatment program too demanding, but others indicated it was not sufficiently intensive. Patients assigned to fluoxetine attended more physician visits, exhibited a greater reduction in binge eating and vomiting, and had a greater improvement in psychological symptoms than those assigned to placebo. There was no evidence of benefit from guided self-help.

Conclusions: The treatment of patients with bulimia nervosa in a primary care setting is hampered by a high dropout rate. Guided self-help, a psychological treatment based on cognitive behavior therapy, appears ineffective, but treatment with fluoxetine is associated with better retention and substantial symptomatic improvement.

Citing Articles

Effectiveness of Online and Remote Interventions for Mental Health in Children, Adolescents, and Young Adults After the Onset of the COVID-19 Pandemic: Systematic Review and Meta-Analysis.

Fischer-Grote L, Fossing V, Aigner M, Fehrmann E, Boeckle M JMIR Ment Health. 2024; 11:e46637.

PMID: 38315524 PMC: 10877489. DOI: 10.2196/46637.


Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations.

Edinoff A, Fort J, Woo J, Causey C, Burroughs C, Cornett E Neurol Int. 2021; 13(3):445-463.

PMID: 34564289 PMC: 8482107. DOI: 10.3390/neurolint13030044.


Psychotherapy and Medications for Eating Disorders: Better Together?.

Reas D, Grilo C Clin Ther. 2020; 43(1):17-39.

PMID: 33342555 PMC: 8243253. DOI: 10.1016/j.clinthera.2020.10.006.


Treatment outcomes for eating disorders in Sweden: data from the national quality registry.

Sodersten P, Brodin U, Sjoberg J, Zandian M, Bergh C BMJ Open. 2019; 9(1):e024179.

PMID: 30647041 PMC: 6340438. DOI: 10.1136/bmjopen-2018-024179.


Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa.

McElroy S, Guerdjikova A, Mori N, Romo-Nava F CNS Drugs. 2018; 33(1):31-46.

PMID: 30523523 DOI: 10.1007/s40263-018-0594-5.